Anthropic, the artificial intelligence company behind the Claude family of models, is moving toward an initial public offering that could value the company at approximately $1.5 trillion. That figure falls short of earlier expectations, which had pegged a potential valuation at $2 trillion. Even at the lower number, a listing of that size would rank among the largest debuts in IPO history, a measure of how much value has accrued to frontier AI developers.

The prospect of a listing has raised concerns about the risks the offering could pose to 401(k) investments, particularly as debates over AI safety continue. Those concerns trace to how retirement savings reach public markets: 401(k) plans, the employer-sponsored accounts used by millions of American workers, typically hold shares of newly public companies through index and target-date funds. Recent draft-prospectus disclosures from Anthropic highlight potential catastrophic risks associated with advanced AI — language that is striking by the standards of ordinary offering documents and that could influence investor sentiment and market dynamics around the deal.

Institutional scrutiny of the process has intensified. New York City Comptroller Mark Levine, who helps oversee the retirement funds of New York City's public employees, has urged a pause in the IPO until Anthropic provides more comprehensive safety and governance disclosures.

Market pricing suggests participants view the Anthropic IPO as potentially facing downward valuation pressure tied to AI safety concerns. The current environment points to a cautious stance among investors, with a significant portion of activity concentrated in lower valuation brackets. Participants are also monitoring Anthropic's disclosures closely, as they could significantly influence how the offering is received and ultimately valued.

Attention now turns to Anthropic's filing updates and any communication from its leadership. New safety disclosures or governance measures could affect investor sentiment and market pricing. Regulatory responses, along with further comments from institutional figures such as Levine, may indicate whether the IPO timeline faces delays or adjustments.

Such developments could shift market expectations and alter the perceived risks associated with the offering — and, in turn, its potential valuation.